The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.

Abstract

Multiple myeloma represents an incurable disease, for which development of new therapies is required. Here, we report the effect on myeloma cells of LBH589, a new hydroxamic acid-derived histone deacetylase inhibitor. LBH589 was a potent antimyeloma agent (IC(50) < 40 nmol/L) on both cell lines and fresh cells from multiple myeloma patients, including cells… (More)

Topics

6 Figures and Tables

Cite this paper

@article{Maiso2006TheHD, title={The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.}, author={Patricia Maiso and Xonia Carvajal-Vergara and Enrique Mar{\'i}a Ocio and Ricardo L{\'o}pez-P{\'e}rez and Gema Mateo and Norma Carmen Guti{\'e}rrez and Peter W Atadja and Atanasio Pandiella and Jes{\'u}s Fernando San Miguel}, journal={Cancer research}, year={2006}, volume={66 11}, pages={5781-9} }